A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.
Doi T, Takahashi S, Aoki D, Yonemori K, Hara H, Hasegawa K, Takehara K, Harano K, Yunokawa M, Nomura H, Shimoi T, Horie K, Ogasawara A, Okame S.
Doi T, et al. Among authors: ogasawara a.
Cancer Chemother Pharmacol. 2024 Feb 27. doi: 10.1007/s00280-023-04631-7. Online ahead of print.
Cancer Chemother Pharmacol. 2024.
PMID: 38411735